Navigation Links
The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh

Cognition Therapeutics, Inc. Begins Operations with a $200,000 Investment

from the PLSG

PITTSBURGH, Dec. 4 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the organization providing capital investments and customized company formation and business growth services to the region's life sciences enterprises, announced that the PLSG has helped Cognition Therapeutics, Inc. (Cognition) make the decision to relocate to southwestern Pennsylvania and has invested $200,000 in the Company. In addition, the PLSG has assisted Cognition in establishing regional operations and has provided connections to additional capital and equipment sources. The Cognition team is occupying office space in the PLSG Incubator and laboratory space on the South Side.

Cognition is an early-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain.

The societal costs of neurodegenerative diseases are enormous; Alzheimer's disease (AD) is the most common cognitive dementia, affecting one of every ten people over age 65 and nearly 35% over age 85. This translates into more than 4.5 million AD patients in the U.S. alone, a number expected to reach 9 million by 2030 and 16 million by 2050 as the U.S. population ages. Currently, there are no treatments to address AD or its progression; available drugs treat only the symptoms without modifying the disease.

Cognition will leverage its proprietary and synergistic phenotypic assay and chemistry technology to create novel small molecule libraries, and then rapidly screen these libraries in models of the memory loss that characterize the earliest stages of Alzheimer's disease. PLSG's investment will support the deployment of the phenotypic assay technology platform. "Our approach is to target the toxic proteins that build up in the brains of elderly individuals and results in memory loss that eventually progresses to degeneration of brain cells. Evidence suggests that blocking this protein and its toxic actions early on in the course of the disease will prevent or reverse memory loss," said Dr. Susan Catalano, Chief Science Officer and inventor of the phenotypic assay platform technology.

"We are thrilled to welcome Cognition to southwestern Pennsylvania and to our investment portfolio," said John W. Manzetti, PLSG President & CEO. "Cognition is the 10th company that the PLSG has helped relocate to the region. In addition to our efforts to grow companies from regional sources, it is essential that we also import companies and technologies to the region that will increase the commercialization of innovative healthcare solutions which can have global impact and multiple market applications." Mr. Manzetti continued, "Cognition's development of novel therapies for neurodegenerative diseases has the potential to address the global epidemic of Alzheimer's disease. Even small delays in Alzheimer's onset and progression can significantly reduce the disease's devastation." Mr. Manzetti added, "we look forward to helping build Cognition into a successful regional life sciences company."

"Pittsburgh is a perfect location for Cognition," said Tony Giordano, CEO of Cognition. "The region's strong life sciences research infrastructure, clinical prowess and the PLSG's community of life sciences entrepreneurs will help us gain access to the resources necessary to expedite the development of our technology platforms."

"We are very excited to be establishing our drug discovery operations here. Pittsburgh's neuroscience research community is recognized for its leadership within the field, and this will allow us to staff our company with world-class neurobiologists," said Dr. Franz Hefti, Chairman of Cognition's Board of Directors.

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The PLSG invests in and supports the growth of biosciences companies in southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region's talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region.

About Cognition Therapeutics, Inc. (Cognition)

Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small molecule drug candidates.

SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)...  ARKRAY USA , Inc., a ... demonstrating the accuracy of its blood glucose meter systems. ... Diabetes and Cardiovascular Disease in Los Angeles ... ® 01 meter and the Assure ® ... to accurately measure glucose levels in blood is essential ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 15th by ... handling security in light of the recent terrorist attacks in Paris, other cities are ... an attack from reaching U.S. soil. Especially around special events that may be high-profile ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
Breaking Medicine News(10 mins):